Changes in cell-surface peptidase activity in papillary renal cell carcinoma

Anticancer Research

Volumn 30, Issue 4, 2010, Pages 1137-1141

  Blanco, Lorena ^a   Perez, Itxaro ^a   Sanz, Begoña ^a   Gil, Javier ^a   López, José I ^b   Ugalde, Aitziber ^c   Varona, Adolfo ^a   Larrinaga, Gorka ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c HOSPITAL DE BASURTO   (Spain)

Author keywords

CD10; CD13; gp160; Papillary carcinoma; Peptidases; Renal tumour behaviour

Indexed keywords

2 NAPHTHYLAMINE; DIPEPTIDYL PEPTIDASE; GLYCOPROTEIN GP 160; MICROSOMAL AMINOPEPTIDASE; PEPTIDASE; PROTEINASE;

AGED; ARTICLE; CATALYSIS; CELL SURFACE; CHROMOSOME 17; CHROMOSOME 7; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; FLUOROMETRY; FROZEN SECTION; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; OUTCOME ASSESSMENT; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION;

AGED; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; CELL MEMBRANE; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; PEPTIDE HYDROLASES;

EID: 77953737684     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer Statistics. CA Cancer J Clin 57: 43-66, 2007.
2. López-Beltrán A, Scarpelli M, Montironi R and Kirkali Z: 2004 WHO classification of the renal tumors of the adults. Eur Urol 49: 798-805, 2006.
3. Eble JN, Sauter G and Epstein JI: 2005 WHO Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004.
4. Delahunt B and Eble JN: Papillary renal cell carcinoma: A clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 10: 537-544, 1997. (Pubitemid 27293491)
5. Jiang F, Richter J, Schraml P, Bubendorf L, Gasser T, Sauter G, Mihatsch MJ and Moch H: Chromosomal imbalances in papillary renal cell carcinoma: Genetic differences between histologic types. Am J Pathol 153: 1467-1473, 1998.
6. Mejean A, Hopirtean V, Bazin JP, Larousserie F, Benoit H, Chrétien Y, Thiounn N and Dufour B: Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality, J Urol 170: 764-767, 2003.
7. Bannasch P and Zerban H: Animal models and renal carcinogenesis. In: Tumors and Tumor-like Conditions of the Kidneys and Urethras Eble JN (ed.). New York: Churchill-Livingstone, 1990.
8. Jin JS, Hsieh DS, Lin YF, Wang JY, Sheu LF and Lee WH: Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol 13: 573-580, 2006.
9. Patraki E and Cardillo MR: Quantitative immunohistochemical analysis of matrilysin 1 (MMP-7) in various renal cell carcinoma subtypes. Int J Immunopathol Pharmacol 20: 697-705, 2007.
10. Carl-McGrath S, Lendeckel U, Ebert M and Röcken C: Ectopeptidases in tumour biology: A review. Histol Histopathol 21: 1339-1353, 2006.
11. Blanco L, Larrinaga G, Pérez I, López JI, Gil J, Agirregoitia E and Varona A: Acid, basic and neutral peptidases present different profiles in chromophobe renal cell carcinoma and in oncocytoma. Am J Physiol-Renal Physiol 294: F850-858, 2008.
12. Varona A, Blanco L, López JI, Gil J, Agirregoitia E, Irazusta J and Larrinaga G: Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma. Am J Physiol-Renal Physiol 292: F780-788, 2007.
13. Sobin LH and Wittekind C: TNM Classification of Malignant Tumors. 6th edition. New York: Wiley-Liss, 2002.
14. Mantle D, Lauffart B, McDermott J and Gibson A: Characterization of aminopeptidases in human kidney soluble fraction. Clin Chim Acta 187: 105-113, 1990. (Pubitemid 20067297)
15. Göhring B, Holzhausen HJ, Meye A, Heynemann H, Rebmann U, Langner J and Riemann D: Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer. Int J Mol Med 2: 409-414, 1998.
16. Martignoni G, Pea M, Brunelli M, Chilosi M, Zamó A, Bertaso M, Cossu-Rocca P, Eble JN, Mikuz G, Puppa G, Badoual C, Ficarra V, Novella G and Bonetti F: CD10 is expressed in a subset of chromophobe renal cell carcinomas. Mod Pathol 17: 1455-1463, 2004.
17. Nanus DM, Bogenrieder T, Papandreou CN, Finstad CL, Lee A, Vlamis V, Motzer RJ, Bander NH, Albino NP and Reuter VE: Aminopeptidase A expression and enzymatic activity in primary human renal cancers. Int J Oncol 13: 261-267, 1998. (Pubitemid 28329213)
18. Ishii K, Usui S, Yamamoto H, Sugimura Y, Tatematsu M and Hirano K: Decreases of metallothionein and aminopeptidase N in renal cancer tissues. J Biochem 129: 253-258, 2001. (Pubitemid 32176175)
19. Avery AK, Beckstead J, Renshaw AA and Corless CL: Use of antibodies to RCC and CD10 in the differential diagnosis of Renal Neoplasms. Am J Surg Pathol 24: 203-210, 2000.
20. Langner C, Ratschek M, Rehak P, Schips L and Zigeuner R. CD10 is a diagnostic and prognostic marker in renal malignancies. Histhopathology 45: 460-467, 2004.
21. Zhou M, Roma A and Magi-Galluzzi C: The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms. Clin Lab Med 25: 247-257, 2005.
22. Cadel S, Piesse C, Gouzy-Darmon C, Cohen P and Foulon T: Arginyl aminopeptidase: In: Aminopeptidases in Biology and Disease. Hooper NM and U Lendeckel (eds.). New York: Kluwer Academic/Plenum Press, pp. 113-126, 2004.
23. Chen X, Wang S, Wu N and Yang CS: Leukotriene A4 hydrolase as a target for cancer prevention and therapy. Curr Cancer Drug Targets 4: 267-283, 2004.
24. Scornik OA and Botbol V: Bestatin as an experimental tool in mammals. Curr Drug Metab 2: 67-85, 2001.
25. Scornik OA and Botbol V: Effects on mammals of the aminopeptidase inhibitor bestatine. In: Aminopeptidases in Biology and Disease. Hooper NM and Lendeckel U (eds.). New York, Kluwer Academic/Plenum Press, pp. 127-143, 2004.
26. Marchiò S, Lahdenranta J, Schlingemann RO, Valdembri D, Wesseling P, Arap MA, Hajitou A, Ozawa MG, Trepel M, Giordano RJ, Nanus DM, Dijkman HB, Oosterwijk E, Sidman RL, Cooper MD, Bussolino F, Pasqualini R and Arap W: Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 5: 151-162, 2004.
27. Mishima Y, Terui Y, Sugimura N, Matsumoto-Mishima Y, Rokudai A, Kuniyoshi R and Hatake K: Continuous treatment of bestatin induces anti-angiogenic property in endothelial cells. Cancer Sci 98: 364-372, 2007.
28. Saitoh Y, Koizumi K, Minami T, Sekine K, Sakurai H and Saiki I: A derivative of aminopeptidase inhibitor (BE15) has a dual inhibitory effect of invasion and motility on tumor and endothelial cells. Biol Pharm Bull 29: 709-712, 2006.
29. Sekine K, Fujii H, Abe F and Nishikawa K: Augmentation of dead ligand-induced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines. Int J Cancer 94: 485-491, 2001.
30. Antczak C, De Meester I and Bauvois B: Ectopeptidases in pathophysiology. Bioessays 23: 251-260, 2001.
31. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.